Pathology-targeted EP4 agonism resolves fibrosis and restores regeneration in a rat model of adolescent Duchenne muscular dystrophy
Authors:
- Nasim KajabadiNKNasim Kajabadi
- Ashok NarasimhanANAshok Narasimhan
- Gang ChenGCGang Chen
- Lin YiLYLin Yi
- Cristina Rodríguez-RodríguezCRCristina Rodríguez-Rodríguez
- Ian F. CoccimiglioICIan F. Coccimiglio
- Tiffany HuangTHTiffany Huang
- Mariana RendeiroMRMariana Rendeiro
- Keitaro YamanouchiKYKeitaro Yamanouchi
- Urs O. HäfeliUHUrs O. Häfeli
- Robert N. YoungRYRobert N. Young
Preprint
Abstract
Duchenne muscular dystrophy (DMD) presents a critical therapeutic gap in adolescent patients, where extensive fibro-fatty muscle replacement and depletion of the regenerative niche render existing interventions insufficient. Prostaglandin E2 signaling through the EP4 receptor stimulates bone and muscle regeneration and repair, but systemic off-target effects have limited the clinical translation of EP4 agonism in diseases such as DMD. We therefore evaluated irodanoprost (IROD), a bone-targeted prodrug of an EP4-selective agonist, in a DMD rat model, comparing early- and late-intervention cohorts. In adolescent rats, 8 weeks of treatment reduced body weight deficit by 41.4% and restored hindlimb muscle mass and maximum tetanic force to wild-type levels. IROD dose-dependently inhibited fibro-adipogenic progenitor differentiation into α-SMA⁺ myofibroblasts, facilitating active resolution of established fibrosis below pre-treatment baseline. This was accompanied by re-activation of a synchronized regenerative program marked by clustered eMHC⁺ fibers, restoring the total myofiber pool to wild-type levels. A strong linear correlation between intramuscular fat reduction and fibrosis resolution suggests that MRI-based fat imaging may serve as a non-invasive surrogate for monitoring anti-fibrotic efficacy. The efficacy of IROD is likely aided by the fact that while it selectively distributes to bone in healthy animals, we observed markedly enhanced accumulation of the drug in dystrophic muscle. These findings establish IROD as a pathology-targeted approach capable of resolving the fibro-fatty niche and restoring regenerative capacity in advanced DMD. Summary: Pathology-targeted EP4 agonism resolves established fibrosis and restores myofiber regeneration in a rat model of adolescent Duchenne dystrophy. GraphicKeywords
This publication has 47 references indexed in Scilit:
- Givinostat: First ApprovalDrugs, 2024
- Cardiovascular Disease in Duchenne Muscular DystrophyJACC: Basic To Translational Science, 2022
- Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular DystrophyJAMA Neurology, 2020
- Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophyCochrane Database of Systematic Reviews, 2017
- Satellite cells from dystrophic muscle retain regenerative capacityStem Cell Research, 2015
- E-type prostanoid receptor 4 (EP4) in disease and therapyPharmacology & Therapeutics, 2013
- Duchenne muscular dystrophy – What causes the increased membrane permeability in skeletal muscle?The International Journal of Biochemistry & Cell Biology, 2011
- Streptomycin reduces stretch-induced membrane permeability in muscles from mdx miceNeuromuscular Disorders, 2006
- Bisphosphonates: A review of their pharmacokinetic propertiesBone, 1996
- Fast muscle fibers are preferentially affected in Duchenne muscular dystrophyCell, 1988